Home Interviews BioStock Investor Pitch: Oncoinvent

BioStock Investor Pitch: Oncoinvent


BioStock Investor Pitch: Oncoinvent

5 January, 2024

Oncoinvent’s CEO Anders Månsson visited BioStock’s studio to talk about the development of the radiopharmaceutical Radspherin for peritoneal carcinomatosis. In his presentation, he delves into the results from the phase I/IIa studies with Radspherin and the upcoming clinical development plan. Furthermore, he talks about Oncoinvent as an investment opportunity and the unmet medical need for these cancer patients. 

Watch Oncoinvent’s CEO Anders Månsson present the company below.

YouTube video

The content of BioStock’s news and analyses is independent but the work of BioStock is to a certain degree financed by life science companies. The above article concerns a company from which BioStock has received financing.

Prenumerera på BioStocks nyhetsbrev